Research programme: DNA therapeutics - RenBio
Latest Information Update: 13 Sep 2024
Price :
$50 *
At a glance
- Originator RenBio
- Class Antibodies; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Influenza virus infections; Zika virus infection
Most Recent Events
- 26 Jul 2024 Preclinical development for Influenza virus infections (Prevention) in USA (Parenteral)
- 26 Jul 2024 Preclinical development for Zika virus infection (Prevention) in USA (Parenteral)
- 05 May 2023 RenBio files patent protection for 'Plasmid DNA constructs for therapeutic protein expression' worldwide